HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer
Status:
RECRUITING
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.
The main questions it aims to answer are:
Can HDAC inhibitors combined with neoadjuvant immunochemotherapy improve the rate of pCR and complete resection in patients? Are HDAC inhibitors combined with neoadjuvant immunochemotherapy safe and reliable? Does the combination of HDAC inhibitors and neoadjuvant immunochemotherapy achieve a better long-term prognosis than neoadjuvant therapy?
Phase:
PHASE2
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Collaborators:
Chongqing General Hospital Chongqing Medical University Chongqing Renji Hospital, University of Chinese Academy of Sciences Chongqing Seventh People's Hospital Chongqing Shapingba District People's Hospital Chongqing Traditional Chinese Medicine Hospital Chongqing University Cancer Hospital First Affiliated Hospital of Chongqing Medical University Southwest Hospital, China The 13th People's Hospital of Chongqing The Second Affiliated Hospital of Chongqing Medical University Xinqiao Hospital of Chongqing
Treatments:
Drug Therapy N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide tislelizumab